Phase I: Determine the maximum tolerated dose (MTD) of Z-208 in patients with advanced hepatocellular carcinoma 28 days [clinicaltrials_resource:fc8a3cc40566dc37806ad87fb780e047]

Phase I: Determine the maximum tolerated dose (MTD) of Z-208 in patients with advanced hepatocellular carcinoma 28 days [clinicaltrials_resource:fc8a3cc40566dc37806ad87fb780e047]

Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:fc8a3cc40566dc37806ad87fb780e047
Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC) [clinicaltrials:NCT00731445]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Phase I: Determine the maximum tolerated dose (MTD) of Z-208 in patients with advanced hepatocellular carcinoma 28 days [clinicaltrials_resource:fc8a3cc40566dc37806ad87fb780e047]

Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:fc8a3cc40566dc37806ad87fb780e047
Bio2RDF identifier
fc8a3cc40566dc37806ad87fb780e047
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:fc8a3cc40566dc37806ad87fb780e047
measure [clinicaltrials_vocabulary:measure]
Phase I: Determine the maximum ...... anced hepatocellular carcinoma
time frame [clinicaltrials_vocabulary:time-frame]
description
Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
identifier
clinicaltrials_resource:fc8a3cc40566dc37806ad87fb780e047
title
Phase I: Determine the maximum ...... patocellular carcinoma 28 days
@en
inDataset
type
label
Phase I: Determine the maximum ...... a3cc40566dc37806ad87fb780e047]
@en